NCT00132015View on ClinicalTrials.gov

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

June 30, 2008

Conditions
Chronic Myeloproliferative DisordersLeukemiaLymphomaNonneoplastic ConditionPrecancerous Condition
Interventions
DRUG

tanespimycin

Trial Locations (2)

20892

NCI - Center for Cancer Research, Bethesda

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00132015 - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis | Biotech Hunter | Biotech Hunter